NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects | Biotech Hunter

Enrollment

351

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

January 23, 2019

Study Completion Date

January 23, 2019

Conditions

Type2 Diabetes Mellitus

Interventions

DRUG

Bexagliflozin tablets, 20 mg

Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.

DRUG

Bexagliflozin tablets, placebo

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

DRUG

Bexagliflozin tablets, 20 mg

Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.

Trial Locations (43)

10036

Clinical Research Site 1368, New York

10455

Clinical Research Site 1275, The Bronx

33024

Clinical Research Site 1372, Hollywood

33026

Clinical Research Site 1373, Pembroke Pines

33461

Clinical Research Site 1362, Palm Springs

35205

Clinical Research Site 1232, Birmingham

35242

Clinical Research Site 1378, Birmingham

36535

Clinical Research Site 1269, Foley

60602

Clinical Research Site 1366, Chicago

63117

Clinical Research Site 1374, St Louis

70124

Clinical Research Site 1294, New Orleans

72209

Clinical Research Site 1363, Little Rock

77051

Clinical Research Site 1369, Houston

78209

Clinical Research Site 1371, San Antonio

78258

Clinical Research Site 1360, San Antonio

78629

Clinical Research Site 1379, Gonzales

83686

Clinical Research Site 1376, Nampa

87102

Clinical Research Site 1286, Albuquerque

89104

Clinical Research Site 1370, Las Vegas

90650

Clinical Research Site 1365, Norwalk

91606

Clinical Research Site 1375, North Hollywood

92805

Clinical Research Site 1381, Anaheim

97239

Clinical Research Site 1019, Portland

06851

Clinical Research Site 1382, Norwalk

08009

Clinical Research Site 1009, Berlin

08611

Clinical Research Site 1037, Trenton

456-0058

Clinical Research Site 6048, Nagoya

003-0023

Clinical Research Site 6050, Sapporo

306-0232

Clinical Research Site 6041, Koga

243-0035

Clinical Research Site 6029, Atsugi

547-0055

Clinical Research Site 6051, Kamakura

221-080

Clinical Research Site 6020, Yokohama

153-0053

Clinical Research Site 6055, Tokyo

577-0803

Clinical Research Site 6046, Higashiosaka

582-0005

Clinical Research Site 6033, Kashihara

560-0082

Clinical Research Site 6013, Toyonaka

332-0012

Clinical Research Site 6052, Kawaguchi

329-0433

Clinical Research Site 6053, Shimotsuke

819-0006

Clinical Research Site 6040, Fukuoka

600-8898

Clinical Research Site 6043, Kyoto

536-0008

Clinical Research Site 6015, Osaka

108-0075

Clinical Research Site 6045, Tokyo

166-0003

Clinical Research Site 6047, Tokyo